Uncategorised - European Medical Journal

Earlier Geriatric Assessment Improves Hip Fracture Outcomes

Early geriatric assessments in older adults with hip fractures are strongly associated with improved recovery, reduced hospital stays, and lower complication rates, according to a new systematic review.

Catheter Ablation in Congenital Heart Disease: Real-World Results

Catheter ablation is highly effective for arrhythmias in congenital heart disease patients, French study confirms.

Prostate Cancer Surgery Rates Drop in Low-Risk Cases

The proportion of radical prostatectomies ending in pGG1 fell from 32.4% in 2010 to just 7.8% by 2020

Metagenomic Profiling Maps Europe-Wide Bronchiectasis Resistomes

Next-generation metagenomic sequencing has uncovered key differences in bronchiectasis pathogens and resistance genes across Europe.

Dementia Diagnoses Drop, But Overall Burden Continues to Rise

Dementia diagnoses decline, but more Americans are living longer with the disease and need ongoing support.

ESPID 2025: Two-Dose Pneumococcal Vaccine Still Effective in Gambia Trial

New findings indicate that a two-dose primary schedule without booster can provide sufficient protection in high-transmission, resource-limited settings.

Navigating Cow’s Milk Allergy in Breastfed Babies

Moreover, the infant’s gut microbiota may play a role in both allergy development and tolerance.

Vagus Nerve Stimulation Linked to Quality of Life Gains in Epilepsy

Vagus nerve stimulation (VNS) not only reduces seizures in patients with epilepsy but also leads to early and sustained improvements in mental health, sleep, and quality of life, according to a new multicenter cohort study.

ES-SCLC Maintenance Outcomes from IMforte Trial: ASCO 2025

First-line maintenance treatment with lurbinectedin and atezolizumab significantly improves survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC), according to primary results from the global Phase III IMforte trial presented at ASCO 2025.

New Oral Therapy Doubles PFS in ESR1+ Breast Cancer: ASCO 2025

A NEW oral therapy may significantly delay disease progression in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, according to results presented at the 2025 ASCO Annual Meeting.